

# Fertility and Reproduction in Male Patients with Ankylosing Spondylitis Treated with Infliximab

SOPHIA PASCHOU, PARASKEVI V. VOULGARI, ILEANA G. VRABIE, IOANNA G. SAOUGOU, and ALEXANDROS A. DROSOS

**ABSTRACT.** *Objective.* To identify male patients who were treated with infliximab and had fathered healthy newborns during their management.

*Methods.* We reviewed medical records of men with ankylosing spondylitis (AS) who were followed up at the Rheumatology Outpatients clinic and were treated with infliximab during the period 2001-2007.

*Results.* We identified 4 patients with AS who had fathered 6 healthy children during infliximab treatment. One patient was also treated with small doses of methotrexate.

*Conclusion.* Limited data are available concerning the effects of infliximab on semen quality. Our cases provide some evidence or reassurance for male patients treated with the anti-tumor necrosis factor- $\alpha$  agent. Further prospective studies are necessary, however, to guide clinicians in decision-making. (First Release Dec 1 2008; J Rheumatol 2009;36:351-4; doi:10.3899/jrheum.080554)

*Key Indexing Terms:*

ANTI-TUMOR NECROSIS FACTOR- $\alpha$  AGENTS

INFLIXIMAB

MALE FERTILITY

Anti-tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ) agents are currently used in the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), psoriasis, and Crohn's disease<sup>1-4</sup>. There is still insufficient evidence related to the risks associated with the use of anti-TNF- $\alpha$  agents in pregnancy. Infliximab, adalimumab, and etanercept belong to category B of the US Food and Drug Administration (FDA) classification. Category B means no evidence of risk in humans. However, 3 cases of VACTERL syndrome (vertebral abnormalities, anal atresia, cardiac defect, tracheoesophageal, renal, and limb abnormalities) have been reported, one with etanercept use<sup>5</sup> and 2 with infliximab<sup>6</sup>. Thus, anti-TNF- $\alpha$  agents should be avoided in pregnancy whenever possible<sup>4</sup>. The role of TNF in the male gonad has been investigated<sup>7-16</sup>. Its implication in testicular functions such as spermatogenesis and in the interactions between immune system and spermatogenesis<sup>7</sup> support the notion that TNF- $\alpha$  has important regulatory properties<sup>8,9</sup>. TNF- $\alpha$  released by spermatids is detected by Sertoli cells and may serve as a paracrine factor regulating spermatoge-

nesis<sup>8</sup>. Another study showed that expression of the Fas ligand, a known inducer of testicular apoptosis, was downregulated by TNF- $\alpha$ . Thus, in the seminiferous tubules germ cell-derived TNF- $\alpha$  may regulate the level of Fas ligand controlling germ cell apoptosis<sup>10</sup>. In addition, human peritubular cells, which are able to secrete potent signaling molecules, are regulated by TNF- $\alpha$ <sup>11</sup>. Studies of the effects of TNF on human sperm motility and apoptosis *in vitro* showed that TNF- $\alpha$  produced sperm chromatin and DNA damage in a concentration- and time-dependent manner<sup>12-14</sup>. These findings may explain the reduction of fertility secondary to upregulated production of TNF- $\alpha$  in men with urogenital infections<sup>14</sup> and inflammatory conditions<sup>13</sup>. Further, *in vitro* studies showed that exposing spermatozoa to pathological concentrations of TNF- $\alpha$  can result in significant loss of their functional and genomic integrity, which can be reversed by infliximab<sup>15</sup>. On the other hand, *in vitro* studies demonstrated that the beneficial effects of TNF- $\alpha$  in the rat seminiferous epithelium can be blocked by infliximab<sup>16</sup>. No other anti-TNF- $\alpha$  agents have been known to affect male or female reproductive processes. Limited data also exist concerning the effects of infliximab on semen quality<sup>17</sup>. The effect of infliximab on male fertility has not been clarified. The aim of our study was to describe male patients who were treated with infliximab and had fathered healthy infants during their management.

## MATERIALS AND METHODS

We reviewed medical records of 85 men with AS who were followed at the Rheumatology Outpatient Clinic from 2001 until 2007. All patients fulfilled the modified New York criteria for AS<sup>18</sup>. Sixty-five patients were treated with infliximab. The treatment schedule and the results have been

From the Rheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina, Ioannina, Greece.

S. Paschou, MD, Fellow in Rheumatology; P.V. Voulgari, MD, Assistant Professor of Rheumatology; I.G. Vrabie, MD, Attending Physician; I.G. Saougou, MD, Fellow in Rheumatology; A.A. Drosos, MD, FACR, Professor of Medicine/Rheumatology, Rheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina.

Address reprint requests to Dr. A.A. Drosos, Rheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina, 45110 Ioannina, Greece.

E-mail: adrosos@cc.uoi.gr; www.rheumatology.gr

Accepted for publication September 4, 2008.

Personal non-commercial use only. The Journal of Rheumatology Copyright © 2009. All rights reserved.

reported<sup>1-3</sup>. Twenty men with AS were treated with nonsteroidal antiinflammatory drugs (NSAID), mostly indomethacin.

RESULTS

There were 65 men with AS, with mean age 33.5 ± 5.4 years and mean disease duration 14.8 ± 6.5 years.

We identified 4 men with AS who had fathered 6 healthy newborns during their treatment (Table 1). All patients responded well to infliximab therapy without adverse events. Infliximab infusions were given every 8 weeks in all patients and the number of infusions ranged between 10 and 31 when they had fathered children. Luteinizing and follicle-stimulating hormones as well as testosterone were not measured because there was no serum available. No unhealthy infants were observed in this cohort. None of our male patients required fertility assistance. Three healthy children were born during the followup period in the cohort of the 20 patients not receiving infliximab. Two patients in the infliximab group were lost from followup.

*Patient 1.* A 30-year-old man was diagnosed with AS in 2004. He had oligoarthritis and axial involvement since 1995 and he was taking NSAID. Infliximab was started in March 2004. The dosage was 5 mg/kg (approximately 350 mg) in a loading dose of Weeks 0, 2, 6, and every 8 weeks thereafter. In August 2005 methotrexate (MTX) was added to his treatment because of high disease activity. Three months later, he was in clinical remission. In March 2006 his wife became pregnant while he was receiving the 14th infusion of infliximab. In December 2006 his wife gave birth to a healthy boy. The patient continues his medical treatment, while his wife gave birth to a second healthy boy in July 2008.

*Patient 2.* A 39-year-old man was diagnosed with AS in 2004. His symptoms had begun in 1989 with morning stiffness, oligoarthritis, low back pain, and uveitis. He started taking MTX and small doses of prednisone in 2004 and infliximab in September 2005. He discontinued MTX in October 2006 because of nausea and vomiting. He continued the treatment with infliximab with clinical improvement. His wife became pregnant while he was on the 10th infusion and gave birth to a healthy child in 2007.

*Patient 3.* A 34-year-old man was diagnosed with AS in 2005, while his initial symptoms presented in 1997. He was treated with NSAID. The first infusion of infliximab was in

January 2005. He responded very well to the treatment and during the 14th infusion of the drug his wife became pregnant. His healthy child was born in 2007.

*Patient 4.* A 36-year-old man was diagnosed with AS in 2002. The disease onset was in 1999. He was treated with infliximab in March 2002. His first child, a healthy boy, was born in December 2004, while the patient was on the 18th infliximab infusion in complete clinical remission. His second child, a healthy girl, was born in October 2007 while he was on the 36th infusion of infliximab.

DISCUSSION

Fertility, reproduction, and pregnancy outcome have been studied in patients with autoimmune diseases. A decreased likelihood of ovulation as compared with the control group has been described in patients with RA<sup>19</sup>, while young adults with a history of juvenile chronic arthritis presented significantly reduced fecundity<sup>20</sup>. In addition, women with scleroderma were more likely than those without scleroderma to have adverse outcomes of pregnancy after the onset of their disease, particularly premature births and small full-term infants<sup>21</sup>. On the other hand, women with AS expect to have the same rate of fertility, course of pregnancy, and normal delivery as the healthy female population<sup>22</sup>. Men with RA had lower levels of testosterone than the healthy men, and a large proportion were considered hypogonadal<sup>23-25</sup>. In addition, rheumatoid flares appear to be associated with prolonged suppression of testicular function<sup>26</sup>. Patients with AS may have periods of decreased libido<sup>27</sup>. Further, patients with spondyloarthropathies have a certain degree of hypogonadism<sup>28</sup>. However, another study showed a small, but not significant reduction in serum total testosterone in patients with AS compared to controls<sup>29</sup>.

Infliximab is a chimeric monoclonal antibody against TNF used in patients with RA, seronegative spondyloarthropathies, psoriasis, and Crohn's disease<sup>1-4</sup>. Allergic reactions, increased risk of infections (especially tuberculosis), autoimmune phenomena, reports of lymphoma, and demyelination disorders constitute the adverse effects of infliximab, similar to those reported with the other anti-TNF-α agents<sup>4,30</sup>.

No maternal toxicity, embryotoxicity, or teratogenicity to infliximab was observed in a murine toxicity model conducted by the manufacturer<sup>31</sup>. Rates of live births, miscar-

Table 1. Characteristics of male patients with ankylosing spondylitis who fathered healthy children during infliximab treatment.

Patient	Age, yrs	Disease Duration, yrs	Dose of Infliximab, mg/kg	Date of First Infusion	No. Infusions During Conception of 1st Child	No. Infusions During Conception of 2nd Child	Concomitant Therapy During Conception
1	30	13	5	31-3-2004	14	24	Methotrexate
2	39	19	5	27-9-2005	10		
3	34	11	5	27-1-2005	14		
4	36	9	5	6-3-2002	14	31	

riages, and therapeutic terminations do not appear to be significantly different in women exposed to infliximab during pregnancy compared to those not exposed to the drug<sup>32</sup>. Thus, according to the FDA guidelines, infliximab is considered to belong to category B in terms of the risk during pregnancy. According to the manufacturer's prescribing information, infliximab should be given to a pregnant woman only if clearly needed<sup>33</sup>. However, there are some reports of women with inflammatory arthropathies, treated with anti-TNF- $\alpha$  inhibitors, who became pregnant and gave birth to healthy children<sup>34</sup>.

Limited information exists concerning the effects of infliximab on male fertility. Available data on the effects of infliximab on semen quality come from a study in patients with inflammatory bowel disease. Comparing pre- and post-infusion semen measures in these patients, there was a significant increase in semen volume after infusion with infliximab, and a trend toward decreased sperm motility, while in some patients there was a significant decrease in normal oval forms<sup>17</sup>. Whether these findings translate into impaired fertility is an area for further investigation.

We describe 4 male patients with AS who had no fertility problems during infliximab treatment. All patients were in remission when their wives became pregnant. These cases provide some evidence of reassurance for men treated with infliximab. However, further prospective studies are necessary to clarify the effects of the drug on male fertility and to guide clinicians in appropriate counselling and therapeutic decision-making.

## REFERENCES

1. Voulgari PV, Alamanos Y, Nikas SN, Bougias DV, Temekonidis TI, Drosos AA. Infliximab therapy in established rheumatoid arthritis: an observational study. *Am J Med* 2005;118:515-20.
2. Venetsanopoulou AI, Voulgari PV, Alamanos Y, Papadopoulos CG, Markatseli TE, Drosos AA. Persistent clinical response of infliximab treatment, over a 4-year period in ankylosing spondylitis. *Rheumatol Int* 2007;27:935-9.
3. Voulgari PV, Venetsanopoulou AI, Exarchou SA, Alamanos Y, Tsifetaki N, Drosos AA. Sustained clinical response and high infliximab survival in psoriatic arthritis patients: a 3-year long-term study. *Semin Arthritis Rheum* 2008;37:293-8.
4. Lin J, Ziring D, Desai S, et al. TNF $\alpha$  blockade in human diseases: an overview of efficacy and safety. *Clin Immunol* 2008;126:13-30.
5. Carter JD, Valeriano J, Vasey FB. Tumor necrosis factor- $\alpha$  inhibition and VATER association: a causal relationship? *J Rheumatol* 2006;33:1014-7.
6. Carter JD, Ladhani A, Ricca L, Valeriano J, Vasey FB. A safety assessment of TNF antagonists during pregnancy: a review of the FDA database [abstract]. *Arthritis Rheum* 2007;56 Suppl:S286-7.
7. Benahmed M. Role of tumor necrosis factor in the male gonad [French]. *Contracept Fertil Sex* 1997;25:569-71.
8. De SK, Chen HL, Pace JL, Hunt JS, Terranova PF, Enders GC. Expression of tumor necrosis factor- $\alpha$  in mouse spermatogenic cells. *Endocrinology* 1993;133:389-96.
9. Delfino FJ, Boustead JN, Fix C, Walker WH. NF- $\kappa$ B and TNF- $\alpha$  stimulate androgen receptor expression in Sertoli cells. *Mol Cell Endocrinol* 2003;201:1-12.
10. Pentikainen V, Erkkilä K, Suomalainen L, et al. TNF $\alpha$  down-regulates the Fas ligand and inhibits germ cell apoptosis in the human testis. *J Clin Endocrinol Metab* 2001;86:4480-8.
11. Schell C, Albrecht M, Mayer C, Schwarzer JU, Frungieri MB, Mayerhofer A. Exploring human testicular peritubular cells: identification of secretory products and regulation by tumor necrosis factor- $\alpha$ . *Endocrinology* 2008;149:1678-86.
12. Eisermann J, Register KB, Strickler RC, Collins JL. The effect of tumor necrosis factor on human sperm motility in vitro. *J Androl* 1989;10:270-4.
13. Estrada LS, Champion HC, Wang R, et al. Effect of tumour necrosis factor- $\alpha$  (TNF- $\alpha$ ) and interferon- $\gamma$  (IFN- $\gamma$ ) on human sperm motility, viability and motion parameters. *Int J Androl* 1997;20:237-42.
14. Perdichizzi A, Nicoletti F, La Vignera S, et al. Effects of tumour necrosis factor- $\alpha$  on human sperm motility and apoptosis. *J Clin Immunol* 2007;27:152-62.
15. Said TM, Agarwal A, Falcone T, Sharma RK, Bedaiwy MA, Li L. Infliximab may reverse the toxic effects induced by tumor necrosis factor  $\alpha$  in human spermatozoa: an in vitro model. *Fertil Steril* 2005;83:1665-73.
16. Suominen JS, Wang Y, Kaipia A, Toppari J. Tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ) promotes cell survival during spermatogenesis, and this effect can be blocked by infliximab, a TNF- $\alpha$  antagonist. *Eur J Endocrinol* 2004;151:629-40.
17. Mahadevan U, Terdiman JP, Aron J, Jacobsohn S, Turek P. Infliximab and semen quality in men with inflammatory bowel disease. *Inflamm Bowel Dis* 2005;11:395-9.
18. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. *Arthritis Rheum* 1984;27:361-8.
19. Flaisler F, Hedon B, Sany J, Combe B. A study of ovarian function in rheumatoid arthritis. *Rev Rhum Engl Ed* 1995;62:549-54.
20. Ostensen M, Almqvist K, Koksvis HS. Sex, reproduction, and gynecological disease in young adults with a history of juvenile chronic arthritis. *J Rheumatol* 2000;27:1783-7.
21. Steen VD, Medsger TA Jr. Fertility and pregnancy outcome in women with systemic sclerosis. *Arthritis Rheum* 1999;42:763-8.
22. Ostensen M, Husby G. Ankylosing spondylitis and pregnancy. *Rheum Dis Clin North Am* 1989;15:241-54.
23. Cutolo M, Balleari E, Giusti M, Monachesi M, Accardo S. Sex hormone status of male patients with rheumatoid arthritis: evidence of low serum concentrations of testosterone at baseline and after human chorionic gonadotropin stimulation. *Arthritis Rheum* 1988;31:1314-7.
24. Tengstrand B, Carlström K, Hafström I. Bioavailable testosterone in men with rheumatoid arthritis — high frequency of hypogonadism. *Rheumatology Oxford* 2002;41:285-9.
25. Khalkhali-Ellis Z, Handa RJ, Price RH Jr, Adams BD, Callaghan JJ, Hendrix MJ. Androgen receptors in human synoviocytes and androgen regulation of interleukin 1 $\beta$  (IL-1 $\beta$ ) induced IL-6 production: a link between hypoandrogenicity and rheumatoid arthritis? *J Rheumatol* 2002;29:1843-6.
26. Gordon D, Beastall GH, Thomson JA, Sturrock RD. Prolonged hypogonadism in male patients with rheumatoid arthritis during flares in disease activity. *Br J Rheumatol* 1988;27:440-4.
27. Gordon D, Beastall GH, Thomson JA, Sturrock RD. Androgenic status and sexual function in males with rheumatoid arthritis and ankylosing spondylitis. *Q J Med* 1986;60:671-9.
28. Onose G, Peretianu D, Zaharescu J, Motoiu S. Correlations between spondylarthropathic inflammatory troubles and gonadal (androgenic) troubles in men. Study on 30 cases with a new methodological analysis. *Rom J Intern Med* 1995;33:93-111.
29. Mitra D, Elvins DM, Collins AJ. Testosterone and testosterone free index in mild ankylosing spondylitis: relationship with bone mineral density and vertebral fractures. *J Rheumatol*

- 1999;26:2414-7.
30. Gartlehner G, Hansen RA, Jonas BL, Thieda P, Lohr KN. The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. *J Rheumatol* 2006;33:2398-408.
31. Treacy G. Using an analogous monoclonal antibody to evaluate the reproductive and chronic toxicity potential for a humanized anti-TNF $\alpha$  monoclonal antibody. *Hum Exp Toxicol* 2000;19:226-8.
32. Katz JA, Antoni C, Keenan GF, Smith DE, Jacobs SJ, Lichtenstein GR. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis. *Am J Gastroenterol* 2004;99:2385-92.
33. Lin J, Ziring D, Desai S, et al. TNF $\alpha$  blockade in human diseases: an overview of efficacy and safety. *Clin Immunol* 2008;126:13-30.
34. Hyrich KL, Symmons DP, Watson KD, Silman AJ; British Society for Rheumatology Biologics Register. Pregnancy outcome in women who were exposed to anti-tumor necrosis factor agents: results from a national population register. *Arthritis Rheum* 2006;54:2701-2.